2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…2018 American Transplant Congress
Clinical Outcomes of Late Conversion to Once-Daily Tacrolimus after Liver Transplant
BackgroundSince a once-daily tacrolimus (TAC-OD) has been introduced in the field of transplantation, many studies reported advantages of the new drug, such as the better…2018 American Transplant Congress
Persistence and Homing of Autologous Donor-Reactive Ex-Vivo Expanded Regulatory T Cells to Heart Allografts in Lymphodepleted Recipient Monkeys
Surgery, Starzl Transplantation Institute, Pittsburgh, PA.
Background:Infusion of ex vivo expanded regulatory T cells (Treg) is a promising therapy to prevent allograft rejection. Trafficking of Treg to allografts and secondary (2ry)…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…2018 American Transplant Congress
TGR5-Mediated AMPK/mTOR Signaling Regulates Macrophage Migration and Polarization in Liver Ischemia Reperfusion
Background: Although the plasma membrane-bound G protein–coupled bile acid receptor (TGR5) exerts protective roles in various inflammatory diseases, little is known about the effects and…2018 American Transplant Congress
Racial Differences in Rates of Malignant and Infectious Cutaneous Genital Disease after Solid Organ Transplantation
Purpose: To describe the prevalence and types of genital lesions observed in OTRsMethods: This retrospective review included 496 OTRs who underwent full skin examination at…2018 American Transplant Congress
Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study
1US92 Study Group, Salt Lake City; 2Novartis Pharmaceutical Corporation, East Hanover.
Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 138
- Next Page »